Angiogenesis in chronic myeloproliferative diseases detected by CD34 expression

Abstract

Increased bone marrow angiogenesis estimated as bone marrow microvessel density (MVD), or as serum angiogenic factor levels and/or immunohistochemical expression of these factors in bone marrow biopsy has been demonstrated in a variety of hematological disorders including chronic myeloproliferative diseases (MPDs). The aim of this study was to investigate the MVD in 25 cases of myelofibrosis with myeloid metaplasia (MMM). MVD was estimated by CD34 immunohistochemical expression in bone marrow biopsies. A control group of 27 patients without bone marrow disease, eight cases of polycythemia vera (PV), 41 cases of essential thrombocythemia (ET) and nine cases of chronic myeloid leukemia (CML) were also studied. Moreover, in cases with MMM, MVD was correlated with clinical, laboratory, histological parameters and the outcome of the patients. Our study confirmed a significantly higher degree of angiogenesis in MMM, PV, ET and CML compared with controls (P < 0.001, P = 0.0007, P < 0.001 and P = 0.0008, respectively). Angiogenesis was higher in MMM than PV, ET and CML cases (P < 0.001, P < 0.001 and P = 0.008). Increased angiogenesis was correlated with hypercatabolic symptoms in MMM patients (P = 0.009). No correlation with other clinicopathological parameters or clinical outcome was found. However, definitive conclusions regarding the prognostic value of increased angiogenesis may require additional follow-up and a larger group of patients.

Clinical Correlation of Bone Marrow Microvessel Density in Essential Thrombocythemia

“…In agreement, we and others have confirmed this increase in patients with myelofibrosis with myeloid metaplasia (MMM), chronic myeloid leukemia (CML), polycythemia vera (PV) and essential thrombocythemia (ET) [10,11,12,13,14]. Furthermore, angiogenesis has been correlated with unfavorable prognosis in patients with MMM and CML [10, 13].…”

“…As described previously microvessels were identified using immunohistochemical staining for CD34 antigen [14]. CD34 stains endothelial cells and only a small number of hematopoietic cells (blasts).…”

“…Bone marrow MVD had not been demonstrated to have prognostic value. In the present report, we analyzed the clinical significance of MVD in bone marrow of 40 patients with ET [14]. …”

Angiogenesis and vascular endothelial growth factor‐/receptor expression in myeloproliferative neoplasms: correlation with clinical parameters and JAK2‐V617F mutational status

“…Lundberg et al, 2000;Wrobel et al, 2003;Kvasnicka & Thiele, 2004;Panteli et al, 2004;Ponzoni et al, 2004;Zetterberg et al, 2004;Stifter et al, 2005;Steurer et al, 2007;Tzankov et al, 2007), but whether this is a major oncogenic event or the consequence of clonal haematopoietic cell proliferation remains to be clarified. Fig 3. (A) Receiver operating characteristics (ROC) curve for myeloproliferative neoplasms (MPN) indicating a discriminatory potential of the JAK2-V617F mutant allele amount for increased CD105-microvessel density (MVD) defined as MVD >ROC-determined cut-off score best delineating between MPN and control cases (i.e.…”

Assessment of fibrosis and vascularization of bone marrow stroma of chronic myeloid Leukemia patients treated with imatinib mesylate and their relationship with the cytogenetic response

“…The concentration of vessels, or the BM microvessel density (MVD), can easily be investigated by immunohistochemistry in hematological disorders because the BM is a primary site of disease activity and readily accessible tissue. This measurement is also useful for evaluating the prognosis of patients (Panteli et al, 2004).…”